Drug Delivery to the Brain (N4)
January 1-4, 2027
| Location to be Determined
Joy Yu Zuchero and Peter Tessier
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Saturday, January 2, 2027
| 8:00–9:00 AM |
Welcome and Keynote Address |
|
| |
Tony Wyss-Coray †, Stanford University School of Medicine
The Neurovasculature in Health, Disease, and CNS Drug Delivery |
|
| 9:00–11:15 AM |
Mechanisms of BBB Delivery |
|
| |
Roberto Villaseñor †, Roche Innovation Center Basel
in vitro Shuttle Trafficking |
|
| |
Martin Lauritzen †, University of Copenhagen
in vivo Trafficking using Live Imaging |
|
| |
Joy Yu Zuchero, Denali Therapeutics Inc
TfR and CD98hc-Mediated vs. Traditional IgG Delivery |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:15–1:00 PM |
Poster Setup |
|
| 11:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Emerging Principles of CNS Delivery Platform Engineering |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Engineering for Additional Properties of BBB Platforms |
|
| |
Peter Tessier, University of Michigan
Next-Generation Shuttles for Improved CNS Delivery |
|
| |
Jasi Atwal †, Genentech, Inc.
Leveraging FcRn to Enhance Antibody Transport Across the BBB |
|
| |
Viviana Gradinaru †, California Institute of Technology
Engineering AAVs |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Additional Modes of Delivery |
|
| |
Isabelle Aubert †, University of Toronto
Focused Ultrasound Drug Delivery for Alzheimer's Disease |
|
| |
Haiyan Peng †, Alnylam Pharmaceuticals
Intrathecal ASO Delivery |
|
| |
Benjamin E. Deverman †, Broad Institute of MIT and Harvard
AAV Delivery, New RMT Target |
|
| |
Yizhou Dong †, Icahn School of Medicine at Mount Sinai
mRNA/LNP Delivery to CNS/gamma Secretase Targeted BBB Crossing, Delivery of ASOs |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
New RMT Target Biology and Novel Target Screening Strategies |
|
| |
Karen Duffy †, Manifold Bio
in vivo Multiplex Platform |
|
| |
Sang Hoon Lee †, ABL Bio
Igf1R Binding GrabodyB Platform for Brain Delivery |
|
| |
Sophia M. Shi †, Harvard University
BBB Grabody B |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Therapeutics Enabled by BBB Platforms using Preclinical Models |
|
| |
Per-Ola Freskgard †, BioArctic AB
Antibody Delivery |
|
| |
David Ojala †, Sangamo Therapeutics, Inc.
AAV Delivery of Zinc Finger Repressor for PrP |
|
| |
Nina Leksa †, Sanofi
Nanobody Approach for CNS Delivery |
|
| |
Katherine Cygnar †, Regeneron Pharmaceuticals
AAV Liver Transduction to Produce Brain-Targeting Molecules for Pompe Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Emerging Modalities and Future Opportunities in Targeted Brain Delivery |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Preclinical to Clinical Translation |
|
| |
Jens Niewoehner †, Roche Pharma Research and Early Development
Brain Shuttle, Trontinemab |
|
| |
Carole Ho †, Denali Therapeutics Inc.
Utilizing TfR to Deliver IDS for Treatment of Hunter Syndrome |
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
